Abstract
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection and treatment are significant health organizations’ concerns worldwide. Although there is no proven drug license against the virus, a variety of components have under investigation.
Objectives: In this regard, the present study was intended to evaluate the consequences of Sovodak (sofosbuvir/ daclatasvir) treatment in COVID-19 patients compared with Kaletra (lopinavir/ritonavir).
Patients and Methods: This study was conducted as a randomized trial using 120 COVID19 confirmed cases between August 19th and September 19th, 2020, in which subjects were classified into two treatment groups, 58 (Sovodak group) and 54 (Kaletra group). Related statistical operations calculated significant outcomes such as survival rate and hazard ratio by SPSS version 16. Sovodak was composed of sofosbuvir 400mg and daclatasvir 60mg, and Kaletra included lopinavir 400 mg and ritonavir 100 mg.
Results: We observed that there was no significant difference concerning the comorbidities, death, intensive care unit admission, remission. Besides, Kaletra had a higher rate of discharge versus Sovodak [HR=1.551 (95% CI=1.008-2.386), P =0.046] and a better outcome was observed in patients receiving.
Conclusion: Sovodak compared to Kaletra by Hazard plot. Sovodak (sofosbuvir/daclatasvir) therapy in COVID19 cases was accompanied by a significantly higher survival rate and better outcome than Kaletra (lopinavir/ritonavir).
Trial Registration: This study has been registered in the Iranian Registry of Clinical Trials (identifier: IRCT20200328046885N1; https://en.irct.ir/trial/47565, Ethical code #IR.IUMS.FMD.REC.1399.407).